Small-cap stocks: Riskier, yes, but if picked well, risk-reward ratio favours risk-takers; 6 small-caps with upside potential of up to 45%
Small-cap stocks: A 7-point checklist for better returns; 8 small-caps with an upside potential of up to 46%
MSCI adds Coromandel International and Nykaa to Global Standard Index
Invest in the Best
Check two-year estimates on Price, Revenue & Earnings
READ FOR FREE ON APP
Aarti Drugs Share Price
Loading...
| Open | 377.95 |
| High | 380.90 |
| Low | 370.20 |
| Prev Close | 376.10 |
| Volume | 66,283 |
| VWAP(₹) | 375.08 |
Key Metrics
| PE Ratio(x) | 17.41 |
| EPS - TTM(₹) | 21.36 |
| MCap(₹ Cr.) | 3,394.33 |
| MCap Rank | 69 |
| PB Ratio(x) | 2.22 |
| Div Yield(%) | 0.27 |
| Face Value(₹) | 10.00 |
| 52W High(₹) | 564.05 |
| 52W Low(₹) | 318.95 |
| MCap/Sales | 1.14 |
| Beta(1 Month) | 0.61 |
| BV/Share(₹) | 169.74 |
Aarti Drugs share price insights
Rank 470 - ET 5002021 ranking
Quarterly Topline Performance
Company witnessed QoQ revenue growth of 19.59%, which is highest in the last 3 years. (Source: Consolidated Financials)Employee & Interest Expense
Company has spent 1.31% of its operating revenues towards interest expenses and 5.04% towards employee cost in the year ending Mar 31, 2026. (Source: Consolidated Financials)Aarti Drugs Share Price Update
Aarti Drugs Ltd. share price moved down by -1.12% from its previous close of Rs 376.10. Aarti Drugs Ltd. stock last traded price is 371.90
Share Price Value Today/Current/Last 371.90 Previous Day 376.10
Found Insights useful?
Aarti Drugs Share Price Returns
| 1 Day | -1.12% |
| 1 Month | -4.12% |
| 3 Months | 5.22% |
| 1 Year | -20.28% |
| 3 Years | -20.97% |
| 5 Years | -49.39% |
Aarti Drugs Share Recommendations
Mean recosCurrent
HOLD
1 Analysts
Strong
SellSellHoldBuyStrong
Buy
SellSellHoldBuyStrong
Buy
Analyst Trends
| Ratings | Current | 1W Ago | 1M Ago | 3M Ago |
|---|---|---|---|---|
| Strong Buy | - | - | - | - |
| Buy | - | - | - | - |
| Hold | 1 | 1 | 1 | 1 |
| Sell | - | - | - | - |
| Strong Sell | - | - | - | - |
| # Analysts | 1 | 1 | 1 | 1 |
Recent Recos
- Target₹536
- OrganizationAxis Securities
- BUY
- Target₹570
- OrganizationAxis Securities
- BUY
- Target₹540
- OrganizationPrabhudas Lilladher
- BUY
News & Analysis
Financials
Mar 2026 Dec 2025 Sep 2025 Jun 2025 Mar 2025 Total Income 721.06 602.94 652.88 590.82 678.63 Total Income Growth (%) 19.59 -7.65 10.50 -12.94 19.37 Total Expenses 642.54 564.62 584.77 531.15 598.32 Total Expenses Growth (%) 13.80 -3.45 10.10 -11.23 17.62 EBIT 78.52 38.32 68.11 59.67 80.31 EBIT Growth (%) 104.91 -43.74 14.14 -25.70 34.23 Profit after Tax (PAT) 55.19 40.54 45.28 53.91 62.86 PAT Growth (%) 36.14 -10.47 -16.01 -14.24 69.66 EBIT Margin (%) 10.89 6.36 10.43 10.10 11.83 Net Profit Margin (%) 7.65 6.72 6.94 9.12 9.26 Basic EPS (₹) 6.05 4.44 4.95 5.91 6.88 All figures in Rs Cr, unless mentioned otherwise
InsightsQuarterly Topline Performance
Company witnessed QoQ revenue growth of 19.59%, which is highest in the last 3 years. (Source: Consolidated Financials)Employee & Interest Expense
Company has spent 1.31% of its operating revenues towards interest expenses and 5.04% towards employee cost in the year ending Mar 31, 2026. (Source: Consolidated Financials)
Annual FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 Total Assets 2,815.26 2,574.68 2,432.36 2,421.40 2,207.96 Total Assets Growth (%) 9.34 5.85 0.45 9.67 25.02 Total Liabilities 1,266.03 1,205.34 1,150.40 1,228.73 1,171.66 Total Liabilities Growth (%) 5.04 4.77 -6.37 4.87 37.42 Total Equity 1,549.23 1,369.34 1,281.95 1,192.67 1,036.30 Total Equity Growth (%) 13.14 6.82 7.49 15.09 13.45 Current Ratio (x) 1.59 1.60 1.66 1.60 1.48 Total Debt to Equity (x) 0.37 0.45 0.44 0.51 0.52 Contingent Liabilities 0.00 306.94 281.02 262.94 211.49 All figures in Rs Cr, unless mentioned otherwise
Annual FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 Net Cash flow from Operating Activities 253.54 244.58 358.92 134.20 69.64 Net Cash used in Investing Activities -173.41 -164.63 -223.65 -163.97 -148.86 Net Cash flow from Financing Activities -77.44 -82.12 -136.03 16.54 92.03 Net Cash Flow 2.69 -2.17 -0.76 -13.23 12.80 Closing Cash & Cash Equivalent 7.27 4.58 6.74 8.38 21.61 Closing Cash & Cash Equivalent Growth (%) 58.83 -32.12 -19.57 -61.21 145.23 Total Debt/ CFO (x) 2.27 2.50 1.57 4.52 7.73 All figures in Rs Cr, unless mentioned otherwise
InsightsIncrease in Cash from Investing
Company has used Rs 173.41 cr for investing activities which is an YoY increase of 5.33%. (Source: Consolidated Financials)
Annual FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 Return on Equity (%) 12.58 12.28 13.37 13.94 19.78 Return on Capital Employed (%) 12.92 14.25 16.43 17.29 22.92 Return on Assets (%) 6.92 6.53 7.04 6.86 9.28 Interest Coverage Ratio (x) 9.24 8.46 9.56 9.25 16.42 Asset Turnover Ratio (x) 0.95 0.95 1.04 1.17 1.18 Price to Earnings (x) 14.97 18.45 23.31 18.83 19.38 Price to Book (x) 1.88 2.27 3.11 2.62 3.83 EV/EBITDA (x) 11.17 12.22 14.17 12.10 13.17 EBITDA Margin (%) 12.14 12.71 12.67 11.33 13.69
Found Financials useful?
Share Price Forecast
Exclusively for ETPrime
Invest in the Best
Check two-year estimates on Price, Revenue & Earnings
READ FOR FREE ON APP
Invest in the Best
Check two-year estimates on Price, Revenue & Earnings
READ FOR FREE ON APP
Technicals
No Data Available
- 43%Positive Movement
since 1st Jan 2005
on basis56%Negative Movement
since 1st Jan 2005
on basisExcludeGlobal Meltdown1st Jan 2008 to 10th Nov 2008
Covid Crisis1st Feb 2020 to 31st Mar 2020
R1 - Pivot -
S1 - R2 - S2 - R3 - S3 - 5 Days 14 Days 28 Days - - -
Peer Comparison
- 1D
- 1W
- 1M
- 3M
- 6M
- 1Y
- 5Y
Choose from Peers
Choose from Stocks
Found Peer Comparison useful?
Mutual Funds Ownership
MF Ownership as on 30 April 2026
240.37
Amount Invested (in Cr.)
1.34%
% of AUM
0.00
% Change (MoM basis)
69.05
Amount Invested (in Cr.)
1.03544582%
% of AUM
0.00
% Change (MoM basis)
32.07
Amount Invested (in Cr.)
1.02%
% of AUM
0.00
% Change (MoM basis)
Aarti Drugs Top Searches
Corporate Actions
Board Meeting
Audited Results
May 08, 2026
Board Meeting
Quarterly Results & Interim Dividend
Jan 27, 2026
Board Meeting
Quarterly Results
Nov 03, 2025
Announced on Meeting on May 08, 2026 May 15, 2026 Audited Results Jan 27, 2026 Feb 03, 2026 Quarterly Results & Interim Dividend Nov 03, 2025 Nov 07, 2025 Quarterly Results Jul 15, 2025 Jul 18, 2025 Quarterly Results Apr 29, 2025 May 06, 2025 Audited Results Announced on Ex-Date Dividend% Feb 03, 2025 Feb 09, 2026 20% Jan 29, 2025 Feb 04, 2025 10% Jan 24, 2024 Feb 06, 2024 10% Jan 27, 2023 Feb 08, 2023 10% Jan 31, 2022 Feb 09, 2022 10% Announced on Ex-Date Aug 20, 2020 Sep 30, 2020 Bonus Ratio: 3 share(s) for every 1 shares held Jan 30, 2015 Mar 24, 2015 Bonus Ratio: 1 share(s) for every 1 shares held Jan 15, 1996 May 13, 1996 Bonus Ratio: 1 share(s) for every 2 shares held No Data Available
No Data Available
Announced on Meeting on Sep 01, 2025 Sep 24, 2025 - Aug 26, 2024 - Buy Back of Shares Aug 26, 2024 - Buy Back of Shares Aug 26, 2024 - Buy Back of Shares Aug 26, 2024 - Buy Back of Shares
About Aarti Drugs
Aarti Drugs Ltd., incorporated in the year 1984, is a Small Cap company (having a market cap of Rs 3,394.33 Crore) operating in Pharmaceuticals sector.
Show More
Industry
Key Indices Listed On
BSE SmallCap, BSE Healthcare, BSE AllCap, BSE Next 250 Microcap, Nifty Smallcap 500
Address
Plot No. 198, M.I.D.C.,Tarapur,Palghar District, Maharashtra - 401506
Executive Leadership
CV
Chandrakant V Gogri
Chairman EmeritusPM
Prakash M Patil
Chairman & M.D & CEORC
Rashesh C Gogri
Managing DirectorHM
Harshit M Savla
Joint Managing DirectorShow More
Auditors
Gokhale & Sathe
Kirtane & Pandit LLP
FAQs about Aarti Drugs share
- 1. What's Aarti Drugs share price today and what are Aarti Drugs share returns ?Aarti Drugs share price is Rs 371.90 as on 10 Jun, 2026, 03:57 PM IST. Aarti Drugs share price is down by 1.12% based on previous share price of Rs 366.05. Aarti Drugs share price trend:
- Last 12 Months: Aarti Drugs share price moved down 20.28%
- Last 3 Years: Aarti Drugs Share price moved down by 20.97%
- 2. What is Aarti Drugs's 52 week high / low?Aarti Drugs share price saw a 52 week high of Rs 564.05 and 52 week low of Rs 318.95.
- 3. What are the returns for Aarti Drugs share?Return Performance of Aarti Drugs Shares:
- 1 Week: Aarti Drugs share price moved down by 1.72%
- 4. What is the market cap of Aarti Drugs?Aarti Drugs share has a market capitalization of Rs 3,394.33 Cr. Within Pharmaceuticals sector, it's market cap rank is 69.
- 5. What is the PE & PB ratio of Aarti Drugs?The PE ratio of Aarti Drugs stands at 17.61, while the PB ratio is 2.74.
Top Gainers
As on 03:59 PM | 10 Jun 2026Top Losers
As on 03:59 PM | 10 Jun 2026Trending in Markets
DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).
DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.
By using this site, you agree to the Terms of Service and Privacy Policy.